Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis
Therapeutic Advances in Endocrinology and Metabolism · 2025-10 · 16
DOI: 10.1177/20420188251340137 ↗Kurz gefasst
Fallbericht in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 28.05.2025. Verfasst von Haiyang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Rituximab (RTX) is a humanized chimeric anti-CD20 monoclonal antibody that leads to immunosuppression through rapid depletion of B lymphocytes. It has been demonstrated to be useful in treating both thyroid eye disease (TED) and myasthenia gravis (MG), respectively. However, the effectiveness of RTX in concurrent TED and MG cases is unclear and not previously reported in the literature. In this study, we describe a 13-year-old girl who presented with a 10-year history of general MG and a 1-year history of Graves’ disease, bilateral proptosis, eye motility restriction, and lagophthalmos. A comprehensive evaluation confirmed the diagnosis of concurrent TED and MG. Satisfactory effectiveness was observed after RTX treatment without side effects. Based on the described observations, we suggest that RTX should be further explored as a treatment option for patients with concurrent TED and MG.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Consultant Emerita Division of Endocrinology, Professor of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA.
- State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Huangpu District, Shanghai 200011, China.
ORCID-Profile: Haiyang Zhang, Ting Lu, Yinwei Li, Haixia Guan, Rebecca S Bahn, Huifang Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Lu, T., Li, Y., Guan, H., Bahn, R. S., & Zhou, H. (2025). Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis. Therapeutic Advances in Endocrinology and Metabolism, 16. https://doi.org/10.1177/20420188251340137
Vancouver
Zhang H, Lu T, Li Y, Guan H, Bahn RS, Zhou H. Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis. Therapeutic Advances in Endocrinology and Metabolism. 2025;16. doi:10.1177/20420188251340137
BibTeX
@article{Zhang2025,
author = {Zhang, Haiyang and Lu, Ting and Li, Yinwei and Guan, Haixia and Bahn, Rebecca S and Zhou, Huifang},
title = {Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis},
journal = {Therapeutic Advances in Endocrinology and Metabolism},
year = {2025},
volume = {16},
doi = {10.1177/20420188251340137}
}
EUVIMED